TR201910983T4 - Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. - Google Patents

Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. Download PDF

Info

Publication number
TR201910983T4
TR201910983T4 TR2019/10983T TR201910983T TR201910983T4 TR 201910983 T4 TR201910983 T4 TR 201910983T4 TR 2019/10983 T TR2019/10983 T TR 2019/10983T TR 201910983 T TR201910983 T TR 201910983T TR 201910983 T4 TR201910983 T4 TR 201910983T4
Authority
TR
Turkey
Prior art keywords
disorders
modulators
derivatives
tnf activity
relates
Prior art date
Application number
TR2019/10983T
Other languages
English (en)
Turkish (tr)
Inventor
Peter Alexander Rikki
Hussein Ali Mezher
Alistair Brown Julien
Elizabeth Jackson Victoria
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of TR201910983T4 publication Critical patent/TR201910983T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TR2019/10983T 2013-12-09 2014-12-08 Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. TR201910983T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1321731.0A GB201321731D0 (en) 2013-12-09 2013-12-09 Therapeutic agents

Publications (1)

Publication Number Publication Date
TR201910983T4 true TR201910983T4 (tr) 2019-08-21

Family

ID=50000414

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10983T TR201910983T4 (tr) 2013-12-09 2014-12-08 Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri.

Country Status (11)

Country Link
US (1) US10273247B2 (cg-RX-API-DMAC7.html)
EP (1) EP3080133B1 (cg-RX-API-DMAC7.html)
JP (1) JP6483700B2 (cg-RX-API-DMAC7.html)
CN (1) CN105814065B (cg-RX-API-DMAC7.html)
BR (1) BR112016011522B1 (cg-RX-API-DMAC7.html)
CA (1) CA2930912C (cg-RX-API-DMAC7.html)
ES (1) ES2743190T3 (cg-RX-API-DMAC7.html)
GB (1) GB201321731D0 (cg-RX-API-DMAC7.html)
RU (1) RU2683940C1 (cg-RX-API-DMAC7.html)
TR (1) TR201910983T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015086504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
EP3286195A1 (en) 2015-04-17 2018-02-28 AbbVie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TW201920202A (zh) * 2017-08-17 2019-06-01 瑞士商愛杜西亞製藥有限公司 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
US20240002401A1 (en) * 2020-11-16 2024-01-04 Guangzhou Henovcom Bioscience Co., Ltd. Imidazothiazole compounds, pharmaceutical compositions, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463212A1 (en) * 1990-06-27 1992-01-02 Nikken Chemicals Co., Ltd. Imidazo[2,1-b]thiazole compound anti-ulcer agent containing the same
US5577987A (en) 1994-07-07 1996-11-26 Precise Exercise Equipment Co. Abdominal exerciser device
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
JP2002167389A (ja) * 2000-09-20 2002-06-11 Nikken Chem Co Ltd 新規チアゾールニ環化合物
CA2523336A1 (en) * 2003-04-30 2004-11-11 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
CN1823072A (zh) * 2003-05-15 2006-08-23 艾科尔公司 作为p38抑制剂的咪唑并噻唑和咪唑并噁唑衍生物
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
WO2011132048A1 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
BR112016011522A2 (cg-RX-API-DMAC7.html) 2017-08-08
EP3080133A1 (en) 2016-10-19
US20160376290A1 (en) 2016-12-29
ES2743190T3 (es) 2020-02-18
CN105814065B (zh) 2018-11-23
CN105814065A (zh) 2016-07-27
JP6483700B2 (ja) 2019-03-13
GB201321731D0 (en) 2014-01-22
US10273247B2 (en) 2019-04-30
RU2683940C1 (ru) 2019-04-03
WO2015086504A1 (en) 2015-06-18
RU2016127226A (ru) 2018-01-23
EP3080133B1 (en) 2019-07-10
CA2930912A1 (en) 2015-06-18
BR112016011522B1 (pt) 2022-10-25
JP2016539968A (ja) 2016-12-22
CA2930912C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
TR201909614T4 (tr) Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri.
TR201908447T4 (tr) Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri.
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.
EA201500133A1 (ru) Производные имидазопиразина в качестве модуляторов активности tnf
EA201500130A1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
MX380578B (es) Derivados de imidazol pentaciclicos fusionados.
PH12019502182B1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
BR112016013012A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
EA201892144A1 (ru) Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
CA2931589C (en) Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
TR201908163T4 (tr) Tnf aktivitesinin modülatörleri olarak pirazolopiridin türevleri.
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
BR112016011794A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
BR112018069936A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
BR112016011789A2 (pt) Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf